Proscia Inc.

Proscia is a privately held software company that provides digital and computational pathology solutions, leveraging artificial intelligence to transform cancer diagnosis and research. Headquartered in Philadelphia, PA, USA, its mission is to accelerate pathology's digital transformation, improving efficiency, accuracy, and patient outcomes by moving the field to the center of modern precision medicine.

The company's flagship product is the Concentriq® enterprise pathology platform, which manages workflows, images, and data for life sciences and diagnostic laboratories. Proscia's offerings support various applications from drug discovery and development to clinical diagnostics, biomarker research, and precision medicine, including AI modules like DermAI for dermatopathology. The Concentriq platform has received FDA 510(k) clearance for primary diagnosis in the U.S. and CE-IVDR certification for use in Europe.

Led by Co-Founder and CEO David West, Proscia launched the fifth generation of its AI-native Concentriq platform in June 2026. The company has garnered significant recognition, earning top performance scores in the US and Global Best in KLAS for Digital Pathology in Europe in 2026. Proscia raised $50 million in Series C funding in March 2025, bringing its total funding to $130 million. It serves 16 of the top 20 pharmaceutical companies and is projected to support diagnoses for over 22,000 patients daily in 2025, with a goal of 32,000 patients daily, reflecting substantial growth in 2024.